Verrica Pharmaceuticals prices $75m IPO to fund drug-device skin therapy

Verrica Pharmaceuticals said this week that it plans to offer 5 million shares priced between $14 to $16 apiece, setting its initial public offering at $75 million.
The West Chester, PA-based company expects to use its newly-acquired funds to advance its lead product candidate: a drug-device combination product designed to administer a topical dermatological drug, cantharidin.
Get the full story at our sister site, Drug Delivery Business News.
The post Verrica Pharmaceuticals prices $75m IPO to fund drug-device skin therapy appeared first on MassDevice.

Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Wall Street Beat verricapharmaceuticals Source Type: news